In a recent fireside chat hosted by Healthcare Edge, Marc Hedrick, M.D., President and CEO of Plus Therapeutics, Inc., discussed their groundbreaking targeted radio-therapeutics treatment for central nervous system (CNS) cancer. This innovative treatment utilizes the latest technology and shows promise in potentially treating all forms of cancer in the brain and spinal cord at any stage.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Austin, Texas. They have a unique hybrid virtual drug development model, which enables them to be efficient, cost-effective, and accelerate product development. With a team of talented executives and a network of scientists, engineers, and physicians, the company is well-positioned to make significant advancements in the field.
Dr. Hedrick, a trained general, vascular, and plastic surgeon, has previous experience in executive leadership roles at other biotech companies. His expertise and knowledge in regenerative bioengineering and repair have been instrumental in the development of the targeted radio-therapeutics treatment.
The location of Plus Therapeutics, Inc. in Texas provides strategic advantages, including proximity to renowned cancer institutions, researchers, and potential funding through the Cancer Prevention and Research Institute of Texas (CPRIT). These partnerships and resources contribute to the company’s ability to conduct crucial preclinical and development work.
The fireside chat covered various aspects of the targeted radio-therapeutics treatment, highlighting its potential to revolutionize the treatment of CNS cancer. While the full recording of the chat is available for viewing, it is evident that the combination of advanced technology, scientific expertise, and strategic partnerships puts Plus Therapeutics, Inc. at the forefront of innovative cancer treatments.
It is truly exciting to witness the progress being made in the field of CNS cancer treatment, and Plus Therapeutics, Inc. is poised to make a significant impact. With their novel targeted radio-therapeutics approach, the future looks promising for individuals battling cancer in the brain and spinal cord.
Sources:
– Healthcare Edge
– Plus Therapeutics, Inc.
